Synthetic GHRH(1–29), the minimal active GHRH sequence
PRODUCT PROFILE
Sermorelin
£49.00
Sermorelin is synthetic ghrh(1–29), the minimal active ghrh sequence. Researchers examine it in relation to pituitary gh reserve and short-duration ghrh-receptor stimulation.
Why it is distinct
Closest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
- Evidence stageEstablished
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Sermorelin is synthetic ghrh(1–29), the minimal active ghrh sequence. Researchers examine it in relation to pituitary gh reserve and short-duration ghrh-receptor stimulation.
Research focus+
Researchers use it to study how well the pituitary gland can release growth hormone. It acts briefly and differs from compounds designed for a long-lasting effect.
How the mechanism differs+
Reproduces the active N-terminal portion of natural GHRH and depends on a responsive pituitary.
Evidence and limitations+
Has historical human diagnostic and paediatric-development use; current availability and authorisation vary by jurisdiction.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers use it to study how well the pituitary gland can release growth hormone. It acts briefly and differs from compounds designed for a long-lasting effect.
Reproduces the active N-terminal portion of natural GHRH and depends on a responsive pituitary.
Closest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
Has historical human diagnostic and paediatric-development use; current availability and authorisation vary by jurisdiction.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch file pendingTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability